Zentiva Appeals EU Court Ruling on Urban Wastewater Treatment Directive

Zentiva Challenges EU Court Decision on UWWTD

Zentiva Group a.s. has formally appealed against a recent decision made by the EU Court regarding the Urban Wastewater Treatment Directive (UWWTD), highlighting serious concerns from various stakeholders in the generic pharmaceutical sector. This appeal aims to overturn the court's previous ruling on the case’s admissibility, allowing for a substantive review of its validity.

Background and Context

On April 28, 2026, Zentiva, alongside numerous companies within the generics industry, filed the appeal with the Court of Justice of the European Union (CJEU). The initial ruling had denied these firms the opportunity to contest the proposed legislation effectively. The focus of this appeal is rooted in the assertion that the directive's implementation could significantly jeopardize the availability and affordability of essential medications across Europe.

The UWWTD directive has raised alarm among 24 out of the 27 EU member states, as expressed during a recent EPSCO council meeting. Despite the widespread concerns regarding the implications of the directive, member states have commenced the directive's national enactment.

Dangerous Precedents for Public Health

The directive, in its current form, poses an alarming risk not only to the accessibility of medicines but also to their pricing structures. Every day, millions rely on medications manufactured within the generics sector. Zentiva, a leading European generic drug manufacturer, fully supports efforts to reduce micropollutants in municipal wastewater but vehemently opposes the proposed Extended Producer Responsibility (EPR) scheme. This EPR policy imposes disproportionate financial burdens on pharmaceutical and cosmetic manufacturers, compelling them to bear the costs of pollution remediation that originates from diverse sources outside their production.

Steffen Saltofte, CEO of Zentiva, emphasized the urgency of the matter, stating, "Generic medicines are fundamental to affordable healthcare in Europe. Should excessive costs be imposed on essential medications, their supply becomes economically infeasible, ultimately impacting the patients who depend on them. Balancing environmental protection with public health is crucial; neither should be sacrificed for the other."

The Financial Imbalance

Generics account for roughly 70% of all pharmaceuticals dispensed in Europe, and nine out of ten critical medicines on the EU's essential drug list originate from this sector (IQVIA, 2024). Operating within strict price regulations has constrained generics manufacturers from passing on additional costs, as many member states enforce rigid pricing and reimbursement laws.

Independent studies across various nations have indicated that the costs associated with implementing the UWWTD have been significantly underestimated, leading to potential drug shortages, escalating healthcare costs, and a decline in the competitive edge of the entire industry.

Call for Responsible Environmental Practices

While Zentiva remains committed to environmental stewardship, it argues that the EPR framework established in the UWWTD does not incentivize the creation of greener pharmaceuticals. The current regulatory stipulations do not permit quick adjustments to drug formulations or replacements without undergoing extensive research, regulatory approvals, and safety reviews. Thus, this directive risks escalating costs without delivering substantial environmental benefits, all while deteriorating healthcare access for patients.

The essence of Zentiva’s appeal is to challenge the admissibility ruling of the Tribunal, paving the way for a thorough court review of articles 9 and 10 in conjunction with Annex III of the UWWTD, which allocates a minimum of 80% of the costs for new so-called quaternary wastewater treatment to the manufacturers of pharmaceuticals and cosmetics.

The Bigger Picture

Despite the direct impact on companies like Zentiva and others in the generics sector, the opportunity to adequately present their case has been stripped away. Zentiva is seeking judicial review of the directive to ensure compliance with fundamental EU legal principles and maintain sustainable access to affordable medications for patients across the continent.

With a robust commitment to environmental responsibility, Zentiva has earned recognition for its sustainability efforts, ranking among the top 2% within the pharmaceutical industry according to EcoVadis in 2025. The ongoing commitment to balancing both environmental and public health interests is at the core of Zentiva’s mission.

To learn more about Zentiva and its focus on delivering sustainable healthcare, visit Zentiva’s official website.